 | Up a level |
2023
Seufferlein, T., Uhl, W., Kornmann, M., Alguel, H., Friess, H., Koenig, A., Ghadimi, M., Gallmeier, E., Bartsch, D. K., Lutz, M. P., Metzger, R., Wille, K., Gerdes, B., Schimanski, C. C., Graupe, F., Kunzmann, V., Klein, I., Geissler, M., Staib, L., Waldschmidt, D., Bruns, C., Wittel, U., Fichtner-Feigl, S., Daum, S., Hinke, A., Blome, L., Tannapfel, A., Kleger, A., Berger, A. W., Kestler, A. M. R., Schuhbaur, J. S., Perkhofer, L., Tempero, M., Reinacher-Schick, A. C. and Ettrich, T. J. (2023). Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)da randomized phase II trial of the AIO pancreatic cancer group. Ann. Oncol., 34 (1). S. 91 - 101. AMSTERDAM: ELSEVIER. ISSN 1569-8041
2021
Tempero, M., Oh, D-Y, Tabernero, J., Reni, M., Van Cutsem, E., Hendifar, A., Waldschmidt, D-T, Starling, N., Bachet, J-B, Chang, H-M, Maurel, J., Garcia-Carbonero, R., Lonardi, S., Coussens, L. M., Fong, L., Tsao, L. C., Cole, G., Jr., James, D. and Macarulla, T. (2021). Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: phase III RESOLVE study. Ann. Oncol., 32 (5). S. 600 - 609. AMSTERDAM: ELSEVIER. ISSN 1569-8041